Elan and partner submit Tysabri license application

Biogen Idec and Elan announced today that they have submitted a supplemental Biologics License Application (sBLA) for multiple-sclerosis drug Tysabri to the US Food and Drug Administration (FDA).

The sBLA includes integrated safety assessment of patients treated with Tysabri in clinical trials and a revised label and risk-management plan.